Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 16/20 | 1.00 |
| ▸ | KIT | P10721 | 13/20 | 1.00 |
| ▸ | BCR | P11274 | 12/20 | 1.00 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 9/20 | 0.84 |
| ▸ | ABL2 | P42684 | 4/20 | 0.84 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.84 |
| ▸ | PLK4 | O00444 | 1/20 | 0.84 |
| ▸ | DDX3X | O00571 | 1/20 | 0.84 |
| ▸ | GAK | O14976 | 1/20 | 0.84 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.84 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.84 |
| ▸ | CA12 | O43570 | 1/20 | 0.84 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.84 |
| ▸ | EGFR | P00533 | 1/20 | 0.84 |
| ▸ | CA1 | P00915 | 1/20 | 0.84 |
| ▸ | CA2 | P00918 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 1/20 | 0.84 |
| ▸ | ALB | P02768 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL846536 | 1.00 | ABL1 (1.00) | ABL1KITBCRLRRK2PDGFRA | |
| SCHEMBL4405514 | 0.97 | ABL1 (1.00) | ABL1KITBCRLRRK2PDGFRA | |
| SCHEMBL3064834 | 0.95 | ABL1 (0.90) | ABL1KITBCRLRRK2PDGFRA | |
| SCHEMBL3264382 | 0.95 | ABL1 (0.90) | ABL1KITBCRLRRK2PDGFRA | |
| SCHEMBL31553098 | 0.95 | ABL1 (0.94) | ABL1KITBCRLRRK2PDGFRA | |
| SCHEMBL19586397 | 0.94 | ABL1 (0.89) | ABL1KITBCRLRRK2PDGFRA | |
| SCHEMBL4394539 | 0.93 | ABL1 (0.88) | ABL1KITBCRLRRK2PDGFRA | |
| SCHEMBL3058299 | 0.93 | ABL1 (0.86) | ABL1KITBCRLRRK2PDGFRA | |
| SCHEMBL12127861 | 0.92 | ABL1 (0.90) | ABL1KITBCRLRRK2PDGFRA | |
| SCHEMBL4399517 | 0.92 | ABL1 (0.87) | ABL1KITBCRLRRK2PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4291889-B1 | USE OF LOW-BIND SURFACE COATINGS FOR ANALYSIS OF TYROSINE KINASE INHIBITORS | MICROMASS LTD (GB) | 2025-03-12 | — | — | EP | claimed |
| US-12222334-B2 | Use of low-bind surface coatings for analysis of tyrosine kinase inhibitors | MICROMASS UK LIMITED (GB) | 2025-02-11 | — | — | US | claimed |
| EP-4291889-A1 | USE OF LOW-BIND SURFACE COATINGS FOR ANALYSIS OF TYROSINE KINASE INHIBITORS | Micromass UK Limited (GB) | 2023-12-20 | — | — | EP | claimed |
| CN-115144511-B | Kit for detecting concentration of various tyrosine kinase inhibitors and preparation method and application thereof | 北京豪思生物科技股份有限公司 | 2023-10-27 | — | — | CN | claimed |
| WO-2022229631-A1 | USE OF LOW-BIND SURFACE COATINGS FOR ANALYSIS OF TYROSINE KINASE INHIBITORS | MICROMASS UK LTD. (GB) | 2022-11-03 | — | — | WO | claimed |
| US-20220341896-A1 | USE OF LOW-BIND SURFACE COATINGS FOR ANALYSIS OF TYROSINE KINASE INHIBITORS | MICROMASS UK LIMITED (GB) | 2022-10-27 | — | — | US | claimed |
| CN-115144511-A | Inhibitor for detecting multiple tyrosine kinases kit for medicine concentration and preparation method and application thereof | 北京豪思生物科技股份有限公司 | 2022-10-04 | — | — | CN | claimed |
| EP-4561530-A1 | IMATINIB FORMULATION FOR PARENTERAL ADMINISTRATION | Artorange Ltd. (CY) | 2025-06-04 | — | — | EP | disclosed |
| CN-119816297-A | Parenteral formulation of imatinib | 阿尔托润吉有限公司 | 2025-04-11 | — | — | CN | disclosed |
| EP-4291889-B1 | USE OF LOW-BIND SURFACE COATINGS FOR ANALYSIS OF TYROSINE KINASE INHIBITORS | MICROMASS LTD (GB) | 2025-03-12 | — | — | EP | disclosed |
| US-12222334-B2 | Use of low-bind surface coatings for analysis of tyrosine kinase inhibitors | MICROMASS UK LIMITED (GB) | 2025-02-11 | — | — | US | disclosed |
| US-20240325390-A1 | IMATINIB FORMULATIONS, MANUFACTURE, AND USES THEREOF | Aerovate Therapeutics, Inc. (US) | 2024-10-03 | — | — | US | disclosed |
| CN-114155918-B | Method for testing potential FASN inhibitor in drug compound library based on molecular docking and molecular dynamic simulation screening | 中国科学院大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-110402244-B | Salts of LSD1 inhibitors | 因赛特公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2022229631-A1 | USE OF LOW-BIND SURFACE COATINGS FOR ANALYSIS OF TYROSINE KINASE INHIBITORS | MICROMASS UK LTD. (GB) | 2022-11-03 | — | — | WO | disclosed |
| US-20220341896-A1 | USE OF LOW-BIND SURFACE COATINGS FOR ANALYSIS OF TYROSINE KINASE INHIBITORS | MICROMASS UK LIMITED (GB) | 2022-10-27 | — | — | US | disclosed |
| CN-115144511-A | Inhibitor for detecting multiple tyrosine kinases kit for medicine concentration and preparation method and application thereof | 北京豪思生物科技股份有限公司 | 2022-10-04 | — | — | CN | disclosed |
| WO-2022109458-A1 | IMATINIB FORMULATIONS, MANUFACTURE, AND USES THEREOF | Aerovate Therapeutics, Inc. (US) | 2022-05-27 | — | — | WO | disclosed |
| EP-3968963-A1 | IMATINIB FORMULATIONS, MANUFACTURE, AND USES THEREOF | Aerovate Therapeutics, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| CN-114155918-A | Potential FASN inhibitor test method in drug compound library based on molecular docking and molecular dynamic simulation screening | 中国科学院大学 | 2022-03-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325390-A1 | IMATINIB FORMULATIONS, MANUFACTURE, AND USES THEREOF | ABL1, ALK, ABL2 | ABL1 1/4885KIT 6/4885BCR 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.